Depression makes people less responsive to chemotherapy: Study

Image
ANI Washington D.C. [USA]
Last Updated : Dec 18 2016 | 4:57 PM IST

A new study reveals depression can reduce the effects of a brain-boosting protein, which plays an important role in how well people respond to chemotherapy.

The findings, presented at ESMO Asia 2016 Congress in Singapore, stated that cancer patients suffering depression have decreased amounts of brain-derived neurotophic factor (BDNF) in their blood.

Low levels make people less responsive to cancer drugs and less tolerant of their side-effects.

Patients with severe depression had lower levels of the protein in the blood so their bodies were not as effective at fighting cancer. This reduced their chance of surviving the disease.

"It's crucial doctors pay more attention to the mood and emotional state of patients. Depression can reduce the effects of chemotherapy and BDNF plays an important role in this process," said lead study author Yufeng Wu from Zhengzhou University in China.

BDNF is essential for healthy brain function and low levels have already been linked with mental illness.

This study aimed to discover how depression influenced outcomes for people with advanced lung cancer.

The researchers recruited 186 newly diagnosed patients receiving chemotherapy.

To assess their state of mind, they were asked to rate their depression levels the day before treatment began.

Their quality of life details, overall survival and other data were also collected. This allowed researchers to compare this information with the patients' mood scores.

The results showed that those whose cancer had spread to other organs were the most depressed and this severely decreased their tolerance to chemotherapy.

It was associated with vomiting, a reduction in white blood cells and prolonged hospital stays.

The impact of severe depression was even greater. It reduced the length of time that patients lived with the disease without it getting worse.

They found that BDNF clearly boosted the number of tumour cells killed by chemotherapy.

"Our aim now is to prescribe drugs such as fluoxetine to depressed patients and study their sensitivity to chemotherapy," added Wu.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 18 2016 | 4:42 PM IST

Next Story